Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04769687
Other study ID # API/2016/76 2019-A00850-57
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 21, 2020
Est. completion date November 1, 2023

Study information

Verified date July 2022
Source Centre Hospitalier Universitaire de Besancon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Main objective: To assess the effectiveness of treatment with symbiotics on the chronic systemic inflammation observed in chronic renal failure 4 months after the start of treatment.


Description:

During a consultation in the nephrology departments : the study will be presented to the patient and the information leaflet will be given to him. During a subsequent visit, after checking the level of serum CRP and obtaining the consent of the investigating physician, a blood test will be taken to assess the intestinal permeability and the inflammatory state. A health-related quality of life (SF-36) and frailty questionnaire (previous questionnaire, MNA questionnaire; Mini Nutritional Assessment - Short Form and physical activity question) will be completed by the patient. Two faecal sampling kits (one for D0 and one for M2) will be distributed to patients. During the D0 visit, patients will be randomized into two arms. Both arms will receive the same dietary advice. The intervention group will receive symbiotics (prebiotics: Orafti®Synergy1 and probiotics: Vivomixx®) for 8 weeks against a placebo in the control group. The treatment will begin after the collection of the first stools (kit J0). At the end of the treatment (M2 or 56 days later), a new blood sample will be taken. Two other blood samples will be taken 4 months and 6 months after the start of treatment. Patients will also provide a faecal sample and complete the various questionnaires at the end of treatment (M2), 2 months after (M4) and 4 months after (M6) treatment. The study will have no influence on the management of the patient. It does not require any additional consultation or any particular biological assessment other than that described. Treatments should not be influenced by the study. The samples will be processed without knowledge of the initial characteristics of the patients, nor of their evolution.


Recruitment information / eligibility

Status Recruiting
Enrollment 62
Est. completion date November 1, 2023
Est. primary completion date May 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Men and women aged 18 to 80 inclusive - Women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potential, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches) - Signature of the informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study and that he agrees to participate in the study and to comply with the requirements and restrictions inherent in this study - Affiliation to a French social security scheme or beneficiary of such a scheme. - Patient with type II diabetes - Creatinine clearance less than 45 ml / min / 1.73m² - Serum CRPus level greater than 6 mg / l, evaluated twice from 15 days to 3 months apart - Patient not opposed to the conservation of biological samples for scientific research purposes. Exclusion Criteria: - Legal incapacity or limited legal capacity - Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator - Subject without health insurance - Pregnant woman - Subject being in the period of exclusion from another study or provided for by the "national file of volunteers". - Infectious episode with need for hospitalization less than 1 month old. - Active infection with hepatitis B and / or C virus. - Active or non-progressive infection with HIV. - Antibiotic therapy in the previous 3 months. - Anti-inflammatory treatment. - History of colectomy. - All chronic digestive pathologies.

Study Design


Intervention

Biological:
probiotic Vivomixx®
Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
prebiotic Orafti®Synergy1
Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
Other:
Placebo
Placebo

Locations

Country Name City State
France CHU de Besançon Besançon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary inflammation change in inflammation estimated by the serum CRP concentration <6 mg / L 4 months
Secondary inflammatory cytokines 1 variation of IL-6 At 2, 4 and 6 months after the start of treatment.
Secondary inflammatory cytokines 2 variation of IL-1ß At 2, 4 and 6 months after the start of treatment.
Secondary inflammatory cytokines 3 variation of TNF-a At 2, 4 and 6 months after the start of treatment.
Secondary inflammatory cytokines 4 variation of IL-10 At 2, 4 and 6 months after the start of treatment.
Secondary inflammatory cytokines 5 variation of IL-8 At 2, 4 and 6 months after the start of treatment.
Secondary inflammatory cytokines 6 variation of IFN? At 2, 4 and 6 months after the start of treatment.
Secondary inflammatory circulating monocytes variation At 2, 4 and 6 months after the start of treatment.
Secondary intestinal microbial metabolome modification of the intestinal microbial metabolome (Nuclear magnetic resonance) At 2, 4 and 6 months after the start of treatment.
Secondary intestinal membrane permeability modification of LPS At 2, 4 and 6 months after the start of treatment.
Secondary bacterial translocation 1 modification of CD14s At 2, 4 and 6 months after the start of treatment.
Secondary bacterial translocation 2 modification of iFABP At 2, 4 and 6 months after the start of treatment.
Secondary health-related quality of life SF-36 Health Survey (Short Form) The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. At 2, 4 and 6 months after the start of treatment.
Secondary fragility fragility (= 3 of the following 5 criteria: undernutrition, grip strength and walking speed, assessed exhaustion and physical activity) At 2, 4 and 6 months after the start of treatment.
See also
  Status Clinical Trial Phase
Recruiting NCT02565459 - MSC and Kidney Transplant Tolerance (Phase A) Phase 1
Recruiting NCT01876017 - Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Phase 1/Phase 2
Recruiting NCT02356419 - rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics Phase 1
Withdrawn NCT03019159 - Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis N/A
Completed NCT02047006 - Dose-finding of Rivaroxaban in Hemodialysis Phase 4
Completed NCT01617824 - Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes Phase 4
Completed NCT00828776 - Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure Phase 2/Phase 3
Completed NCT00597753 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3
Terminated NCT00372489 - Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD Phase 2
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00228436 - Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Phase 2
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Completed NCT01879618 - Use Of Fragmin In Hemodialysis Phase 3
Not yet recruiting NCT01346215 - Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure Phase 3
Completed NCT01220843 - FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease Phase 3
Completed NCT01111630 - Study of Erythropoietin (EPO) Administration Schedule Phase 4
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2
Completed NCT00598273 - Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis Phase 3
Completed NCT00597584 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3